Multiple sclerosis journal - experimental, translational and clinical · 2026
Measurement of functional mobility in multiple sclerosis: A crosswalk between the patient-determined disease steps and the Neuro-QoL Lower Extremity Function-Short Form.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gonzalez Alexa S, Garcia Joshua M, Engebretson Eric, Medina Luis D
Аннотация
BACKGROUND: The Patient-Determined Disease Steps (PDDS) and Neuro-QoL Lower Extremity Function-Short Form (Neuro-QoL LEF-SF) are patient-reported outcome measures used to monitor mobility symptoms in multiple sclerosis (MS).
OBJECTIVE: To develop and validate a crosswalk between the PDDS and Neuro-QoL LEF-SF.
METHODS: Using equipercentile equating, we created a crosswalk from a training sample of 619 MS patients (mean PDDS = 2.4 ± 2.3; mean Neuro-QoL LEF-SF = 33.0 ± 8.3). Validation was performed in a separate sample of 147 MS patients (mean PDDS = 0.6 ± 1.2; mean Neuro-QoL LEF-SF = 38.9 ± 2.8). Agreement between original and converted scores was evaluated using paired t-tests and concordance correlation coefficients.
RESULTS: PDDS and Neuro-QoL LEF-SF scores were strongly correlated in both training (r = -0.89) and validity (r = -0.76) samples. No significant differences in change scores were observed. Concordance coefficients of original and converted scores supported good to very good agreement.
CONCLUSION: We developed a crosswalk for the conversion of scores between the PDDS and the Neuro-QoL LEF-SF for patients with MS. Evidence for the preliminary validity of this crosswalk was demonstrated with both the initial training sample and a separate validity sample. This crosswalk facilitates score comparisons and data harmonization across studies and clinical registries using either measure.
OBJECTIVE: To develop and validate a crosswalk between the PDDS and Neuro-QoL LEF-SF.
METHODS: Using equipercentile equating, we created a crosswalk from a training sample of 619 MS patients (mean PDDS = 2.4 ± 2.3; mean Neuro-QoL LEF-SF = 33.0 ± 8.3). Validation was performed in a separate sample of 147 MS patients (mean PDDS = 0.6 ± 1.2; mean Neuro-QoL LEF-SF = 38.9 ± 2.8). Agreement between original and converted scores was evaluated using paired t-tests and concordance correlation coefficients.
RESULTS: PDDS and Neuro-QoL LEF-SF scores were strongly correlated in both training (r = -0.89) and validity (r = -0.76) samples. No significant differences in change scores were observed. Concordance coefficients of original and converted scores supported good to very good agreement.
CONCLUSION: We developed a crosswalk for the conversion of scores between the PDDS and the Neuro-QoL LEF-SF for patients with MS. Evidence for the preliminary validity of this crosswalk was demonstrated with both the initial training sample and a separate validity sample. This crosswalk facilitates score comparisons and data harmonization across studies and clinical registries using either measure.